Annular elastolytic giant cell granuloma after COVID-19 vaccination


https://doi.org/10.4081/dr.2023.9811
Plum Print visual indicator of research metrics
Citations
  • Citation Indexes: 1
Captures
  • Readers: 4
Mentions
  • News Mentions: 1

Authors

  • Viviana Lora Dermatology Unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
  • Arianna Lamberti Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Rome; Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy.
  • Monia Di Prete Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
  • Dario Graceffa Dermatology Unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
  • Carlo Cota
    carlo.cota@ifo.it
    Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.

The pandemic of SARS-CoV-2 during the first years of the 2020s led to a great commitment to develop effective vaccines. Despite the good safety and tolerability profile, vaccines may trigger a broad spectrum of cutaneous side effects. Granulomatous dermatitis has been rarely reported after SARS-CoV-2 mRNA vaccines, but no cases of annular elastolytic giant cell granuloma have been described. Moreover, in our case, it was also associated with a central area of mid-dermal elastolysis, confirming the strong association between these two diseases already reported in the literature. The observation of occasional eosinophils within the infiltrate and the presentation of the cutaneous eruption a few days after the administration of the second dose of the Pfizer/BioNTech (BNT162b2) vaccine are highly suggestive of a drug-related eruption. To our knowledge, this is the first report in the literature of an annular elastolytic giant cell granuloma as an adverse effect of the SARS-CoV-2 vaccination.